J. Goldman & CO LP Cardiff Oncology, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 47,250 shares of CRDF stock, worth $202,702. This represents 0.01% of its overall portfolio holdings.
Number of Shares
47,250Holding current value
$202,702% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
25.2MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$23.1 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$11.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$9.8 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$6.6 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.19 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $186M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...